GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ZyVersa Therapeutics
ZyVersa, a biotech company, shares are highly speculative. Their price reflects not current revenues, but investors' hopes for the success of its developments in treating inflammatory diseases.
Share prices of companies in the market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory diseases by targeting inflammasomes. We've classified it in the Pharma: Kidney category. The chart below shows how investors are evaluating new approaches to treating chronic inflammation.
Broad Market Index - GURU.Markets
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how ZyVersa shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ZVSA - Daily change in the company's share price ZyVersa Therapeutics
For ZyVersa Therapeutics, Inc., a kidney disease treatment company, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in formulas that assess risks and potential in biotech.
Daily change in the price of a set of shares in a market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory and kidney diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing ZVSA stock price movements.
Daily change in the price of a broad market stock, index - GURU.Markets
ZyVersa Therapeutics is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ZyVersa Therapeutics
ZyVersa Therapeutics' year-to-date performance is a story about its drug development for inflammatory diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its inflammasome inhibitor could offer a new approach to treating a wide range of diseases, which is its main scientific bet.
Annual dynamics of market capitalization of the market segment - Pharma kidney
As an early-stage biotech, ZyVersa is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its kidney disease drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ZyVersa Therapeutics, a biopharmaceutical company focused on treating inflammatory and kidney diseases, is a classic biotech company. Its year-over-year market capitalization dynamics reflect a dynamic of clinical data expectations, independent of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ZyVersa Therapeutics
ZyVersa is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its drugs for the treatment of inflammatory and kidney diseases is the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its platforms targeting inflammasomes and cholesterol effectors in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ZyVersa Therapeutics is a biotech company whose value is tied to the success of its developments. The chart below shows that the company's monthly share price fluctuations are not related to overall market movements, but rather reflect investor expectations regarding clinical trial results and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ZyVersa Therapeutics
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, is experiencing high volatility. Weekly stock performance is driven by clinical trial news, reflecting the risks and hopes of drug discovery in this complex area.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
ZyVersa shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ZyVersa Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that ZyVersa's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
ZVSA - Market capitalization of the company ZyVersa Therapeutics
ZyVersa's chart is a financial map of the fight against inflammation. This biotech company's market cap reflects the hopes for its platform for controlling inflammasomes—the key "switches" of inflammatory processes. Its dynamics are a barometer of research progress and the belief that its approach will help treat a wide range of diseases.
ZVSA - Share of the company's market capitalization ZyVersa Therapeutics within the market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company focused on inflammatory and kidney diseases. Its market capitalization reflects the market's valuation of its scientific platform. The company's market capitalization reflects the potential of its developments to create new treatments for a wide range of diseases.
Market capitalization of the market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company focused on treating inflammatory and kidney diseases. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which ZyVersa is seeking new treatment approaches.
Market capitalization of all companies included in a broad market index - GURU.Markets
ZyVersa is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. Its market cap is a financial bet on its scientific platform. Its value reflects investors' expectations for success in these complex areas of medicine.
Book value capitalization of the company, segment and market as a whole
ZVSA - Book value capitalization of the company ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company. Its book value represents its equity. The chart below visualizes its financial resources for research. Its decline reflects the expenditure on drug development.
ZVSA - Share of the company's book capitalization ZyVersa Therapeutics within the market segment - Pharma kidney
ZyVersa Therapeutics is a clinical-stage biotech company. Its value lies in its scientific platform for treating inflammatory diseases. Its tangible asset share will be minimal, typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma kidney
Below you can see the overall book value of the pharmaceutical sector. Compared to this, ZyVersa, which develops drugs for inflammatory and kidney diseases, looks "light." Its value lies in its scientific platform and patents, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. The company's assets are not factories, but a scientific platform and patents. The company's balance sheet is the value of a new approach to extinguishing inflammatory "fires" in the body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ZyVersa Therapeutics
ZyVersa's balance sheet is its cash and patents. Its market capitalization is a bet on its scientific platform. The MvsBCap_Co chart shows how much the "hope" for a new drug is worth compared to the company's current assets.
Market to book capitalization ratio in a market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company developing drugs for the treatment of inflammatory and kidney diseases. Its value lies in its scientific platform. The chart shows a speculative estimate of its potential, which depends entirely on the success of its drugs in clinical trials.
Market to book capitalization ratio for the market as a whole
ZyVersa Therapeutics is a biotech company targeting kidney diseases and inflammation. The market values it not by its existing labs, but by the potential of its scientific developments. This chart demonstrates the hope premium typical of biotech: the market capitalization, reflecting investors' faith in a future drug, is far removed from the balance sheet reality.
Debts of the company, segment and market as a whole
ZVSA - Company debts ZyVersa Therapeutics
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, uses debt to finance the development of its drugs. This chart shows how the company raises capital for research into inflammatory diseases. In the biotech world, debt is a vital resource in the long journey from a scientific idea to a potential cure.
Market segment debts - Pharma kidney
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat inflammatory and kidney diseases. This chart shows how the small biotech manages its capital to fund expensive clinical trials of its innovative scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ZyVersa Therapeutics
ZyVersa Therapeutics is a biotech company developing drugs for kidney disease. Its financial future depends on the success of clinical trials. This chart shows its level of leverage. It indicates high risk: the company is placing a heavy bet on its research and development without stable revenue.
Market segment debt to market segment book capitalization - Pharma kidney
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. Financing clinical trials requires capital. The chart shows how the company's debt load for R&D funding compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
ZyVersa Therapeutics (ZVSA) is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. This chart shows the overall debt burden of the economy. It serves as a contrast to ZVSA's financial model, which, like most biotechs in the R&D phase, is financed by equity rather than debt.
P/E of the company, segment and market as a whole
P/E - ZyVersa Therapeutics
This metric for ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is a bet on its scientific platform. There is no P/E ratio. The company's valuation is based on the potential of its drugs for the treatment of inflammatory and kidney diseases. The chart is extremely sensitive to news about clinical trial results.
P/E of the market segment - Pharma kidney
This is the average P/E for biotech companies. For ZyVersa, which is in early development, it serves as a benchmark. It reflects the overall level of optimism in the sector, providing context for ZyVersa's valuation, which is betting on the success of its scientific platform for treating inflammatory and kidney diseases.
P/E of the market as a whole
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory diseases by targeting inflammasomes, as well as kidney disease. This chart shows the biotech sentiment. It helps understand how the market views the company's scientific platform and its potential in two different but complex therapeutic areas, and the level of risk associated with it.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. This chart reflects analyst expectations for its scientific platform. It shows the potential future profit the market is pricing in, anticipating successful clinical trials.
%20P%2FE%20ZyVersa%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ZyVersa-Therapeutics&v=1772692323056 "Chart of the company's future (projected) P/E ZyVersa Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
ZyVersa Therapeutics, Inc. is a biotech company developing drugs to treat inflammatory and kidney diseases. This chart shows average expectations for the biotech sector. ZyVersa's position may indicate the extent to which investors believe in its scientific platform and the potential of its drug candidates to address complex medical problems.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772692323058 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
ZyVersa Therapeutics is a biotech company focused on inflammatory and kidney diseases. Its value is based on the potential of its scientific developments. Overall market sentiment in this chart influences the availability of capital, but not the likelihood of success of its clinical programs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772692323059 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ZyVersa Therapeutics
ZyVersa Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory and kidney diseases. This graph shows the development pipeline for drugs for complex conditions. The losses reflect clinical trial costs, while future profits depend on the success and approval of its innovative therapeutic platforms.
Profit of companies in the market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. Profitability in this sector, as this chart shows, depends on scientific breakthroughs in understanding complex biological processes. For ZVSA, success hinges on clinical trial results demonstrating the effectiveness of its inflammation-modulating platform.
Overall market profit
ZyVersa Therapeutics, a biopharmaceutical company focused on inflammatory and kidney diseases, operates in a field where innovation is king. Its success hinges on the results of clinical trials. The economic cycle, as illustrated by this graph, doesn't affect patient demand for treatment, but it does play a significant role in the company's ability to attract funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ZyVersa Therapeutics
ZyVersa Therapeutics develops drugs to treat inflammatory and kidney diseases. This chart reflects analyst forecasts, which assess the scientific potential of its developments. The trend reflects the market's confidence in the success of its clinical programs.
%20profit%20of%20the%20company%20ZyVersa%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ZyVersa-Therapeutics&v=1772692323077 "Graph of future (projected) profit of the company ZyVersa Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company developing drugs for the treatment of inflammatory and kidney diseases. Its key development targets inflammasomes, key regulators of inflammation. This chart shows the revenue forecast for the pharmaceutical sector, reflecting the need for new approaches to treating chronic inflammatory conditions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772692323083 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
ZyVersa Therapeutics is a clinical-stage biotech company specializing in inflammatory diseases. Its value is determined by the potential of its developments. The company's overall profit outlook is influenced by investor sentiment. During periods of pessimism, raising capital for risky biotech projects becomes more challenging.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772692323092 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory and kidney diseases. It has no commercial revenue. The chart reflects investors' valuation of its scientific platform. This is a bet on future clinical trial results and the potential of its candidates to create new treatments.
P/S market segment - Pharma kidney
ZyVersa Therapeutics develops drugs to treat inflammatory and kidney diseases. The chart shows the average revenue estimate for the biotech sector. It allows one to assess whether investor expectations for its scientific developments and potential to treat complex diseases are higher or lower than the industry average.
P/S of the market as a whole
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. Its value is based on the potential of its scientific developments. The graph of average market revenue estimates clearly demonstrates that investors are investing in the hope of a medical breakthrough rather than in current cash flows.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory and kidney diseases. This chart visualizes investor expectations for its pipeline, valuing the company based on the potential future revenue from its drug candidates if they are successfully approved.
%20P%2FS%20ZyVersa%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ZyVersa-Therapeutics&v=1772692323120 "The graph of the company's future (projected) P/S ZyVersa Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory diseases, particularly those related to the kidney. This figure shows the average future revenue estimates for pharmaceutical companies. This helps assess how highly investors value ZyVersa's scientific platform and the potential of its candidates to treat complex diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772692323125 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
ZyVersa Therapeutics is a biotech company focused on inflammatory diseases. Its value is driven by scientific breakthroughs. This overall revenue expectation chart is of little significance to the company. Investors are focused on the potential of its platform to treat a wide range of diseases where inflammation plays a key role.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772692323127 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory and kidney diseases. At this stage, the company typically has no sales revenue. Any revenue reflected in this chart likely comes from partnerships funding its research.
Sales of companies in the market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory diseases, particularly those affecting the kidneys. Their platform targets inflammasomes, key components of the innate immune system. This chart shows total revenue in the sector, reflecting investment and scientific progress in the treatment of inflammatory and kidney diseases.
Overall market sales
ZyVersa Therapeutics is a biopharmaceutical company focused on treating inflammatory and kidney diseases. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ZyVersa Therapeutics
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. Its future depends on the success of its clinical trials. This chart reflects the market's assessment of the likelihood of commercial success for its therapeutic developments in these complex areas.
%20sales%20of%20the%20company%20ZyVersa%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ZyVersa-Therapeutics&v=1772692323133 "Schedule of future (projected) sales of the company ZyVersa Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
ZyVersa Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory diseases, including kidney diseases. The chart shows forecasts for the nephrology segment. The company's future depends on the success of its innovative approaches in clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772692323137 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
ZyVersa Therapeutics is a clinical-stage biotech developing drugs for the treatment of inflammatory and kidney diseases. Its future depends on the success of its research and its ability to raise capital. This graph, reflecting investor sentiment, impacts the availability of funding for biotech companies with innovative but unproven platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772692323140 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ZyVersa Therapeutics
ZyVersa Therapeutics is a biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. While in clinical trials, the company incurs significant expenses. This chart illustrates its investments in research, which, if successful, could lead to the development of sought-after and profitable drugs.
Market segment marginality - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. This chart shows the average revenue in the pharmaceutical industry. As a clinical-stage company, its future ability to exceed this metric depends entirely on the success of its platform and the progression of its candidates through the clinical trials.
Market marginality as a whole
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. It is in clinical trials, meaning it has no operating profit and is dependent on capital investment. This gross margin chart clearly demonstrates the gap between its R&D and its stable operating business.
Employees in the company, segment and market as a whole
Number of employees in the company ZyVersa Therapeutics
ZyVersa Therapeutics is a biopharmaceutical company developing treatments for inflammatory and kidney diseases. While in clinical trials, it operates with a small team. This graphic shows the company's small staff of scientists and clinicians focused on advancing its innovative candidates.
Share of the company's employees ZyVersa Therapeutics within the market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company focused on developing drugs for the treatment of inflammatory and kidney diseases. The company's clinical trial team is small, but consists of highly qualified scientists and physicians. This graph reflects its focus on R&D, where value is created not by mass production, but by the concentration of unique scientific expertise.
Number of employees in the market segment - Pharma kidney
ZyVersa Therapeutics, Inc. is a biotech company developing drugs for the treatment of inflammatory and kidney diseases. The chart of its small scientific team's size shows the stages of clinical development. Minor staffing changes may be due to the addition of consultants or specialists to specific phases of research.
Number of employees in the market as a whole
ZyVersa Therapeutics is a clinical-stage biotech company focused on treating inflammatory and kidney diseases. This chart illustrates its focused R&D strategy. A small team of scientists and physicians forms the company's core. Expansion will be a direct result of positive clinical data and preparation for later stages.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ZyVersa Therapeutics (ZVSA)
ZyVersa is a biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. As with most research-stage biotechs, the company's market value is determined by its intellectual property. This chart shows how investors value the potential of its scientific developments (patents) per scientist or R&D employee.
%20of%20the%20company%20ZyVersa%20Therapeutics%20(ZVSA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ZyVersa-Therapeutics-ZVSA&v=1772692323177 "Chart of market capitalization per employee (in thousands of dollars) of the company ZyVersa Therapeutics (ZVSA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
ZyVersa Therapeutics is a biotech company developing drugs to treat inflammatory and kidney diseases. Its value is driven by the potential of its Inflammasome scientific platform. This chart shows how investors value the company's intellectual capital per member of its scientific team.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772692323181 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory and kidney diseases. The chart shows the company's scientific potential score. It reflects how the market values their innovative platform, where the contributions of a small team of scientists can lead to the creation of new drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772692323198 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ZyVersa Therapeutics (ZVSA)
ZyVersa is a clinical-stage biotech company developing drugs for the treatment of inflammatory and kidney diseases. The company is not commercially profitable. This chart shows the net loss (R&D costs) per scientist working on future drugs.
%20Chart%20ZyVersa%20Therapeutics%20(ZVSA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ZyVersa-Therapeutics-ZVSA&v=1772692323201 "Company Profit Per Employee (in thousands of dollars) Chart ZyVersa Therapeutics (ZVSA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
ZyVersa Therapeutics is a clinical-stage biotech company developing drugs to treat inflammatory diseases by targeting the inflammasome. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company is investing in its scientific programs to validate this new approach to treating inflammation.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772692323203 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
ZyVersa Therapeutics is a clinical-stage biotech company focused on treating inflammatory kidney diseases and other pathologies. The company is not commercially profitable. This graph shows a negative value—the investment (loss) per scientist working on developing new therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772692323208 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ZyVersa Therapeutics (ZVSA)
ZyVersa Therapeutics is a clinical-stage biotech company. This graph will reflect its progress in monetizing its research. The increase in revenue per employee will likely be the result of a strategic partnership with a major pharmaceutical company to co-develop its drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ZyVersa-Therapeutics-ZVSA&v=1772692323216 "Sales chart per company employee ZyVersa Therapeutics (ZVSA)")
Sales per employee in the market segment - Pharma kidney
ZyVersa (ZVSA) is a clinical-stage biotech focused on treating inflammatory and kidney diseases. The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity would be zero, as the entire staff is focused on R&D, not sales.
Sales per employee for the market as a whole
ZyVersa Therapeutics is a biotech company focused on inflammatory and kidney diseases. At the R&D stage, this metric reflects investment in the future. A team of scientists is working on developing a platform, and this metric will only increase with the success of clinical trials and the commercialization of their research.
Short shares by company, segment and market as a whole
Shares shorted by company ZyVersa Therapeutics (ZVSA)
ZyVersa (ZVSA) is a biotech company developing drugs to treat inflammatory diseases (through inflammasome inhibitors) and kidney diseases. This chart shows bearish bets. Skepticism reflects the high risks of biotech: investors doubt their scientific platform will lead to an approved drug.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ZyVersa-Therapeutics-ZVSA&v=1772692323221 "Short Shares Chart for the Company ZyVersa Therapeutics (ZVSA)")
Shares shorted by market segment - Pharma kidney
ZyVersa Therapeutics is a biopharmaceutical company developing treatments for inflammatory diseases, including kidney disease. This chart shows the overall bearish sentiment in the biotech sector focused on kidney and inflammatory diseases. The rising price reflects investor skepticism about this complex research segment, where the risk of clinical failure is high.
Shares shorted by the overall market
ZyVersa is an early-stage biotech company. This chart illustrates the overall market pessimism. When fear mounts, investors sell off biotech microcaps en masse. They see ZVSA as a money-burning venture on high-risk R&D and prefer to exit the asset without waiting for news on trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ZyVersa Therapeutics (ZVSA)
ZyVersa Therapeutics (ZVSA) is a biotech company developing drugs to treat inflammatory diseases, particularly those related to the kidneys. This chart measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on early trial data or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ZyVersa-Therapeutics-ZVSA&v=1772692323241 "RSI 14 indicator chart for the company's stock ZyVersa Therapeutics (ZVSA)")
RSI 14 Market Segment - Pharma kidney
ZyVersa is a "biotech" that "tames" inflammation. Their specialty is *inflammasome* (NLRP3) inhibitors for the treatment of *inflammatory* diseases (kidneys, heart). The "Pharma kidney" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is ZVSA's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
ZyVersa (ZVSA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZVSA (ZyVersa Therapeutics)
ZyVersa is a biotech company developing drugs to treat inflammatory and kidney diseases (such as diabetic nephropathy). This chart shows the average target price. Analysts' forecasts are based on an assessment of the clinical data for its lead candidates and their market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZVSA-ZyVersa-Therapeutics&v=1772692323250 "A chart showing analyst consensus forecasts for the expected stock price. ZVSA (ZyVersa Therapeutics)")
The difference between the consensus estimate and the actual stock price ZVSA (ZyVersa Therapeutics)
ZyVersa is a biotech R&D company focused on developing drugs for the treatment of inflammatory diseases (including kidney disease). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their "venture" valuation of the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZVSA-ZyVersa-Therapeutics&v=1772692323256 "A chart showing the difference between the consensus forecast and the actual stock price. ZVSA (ZyVersa Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
ZyVersa (ZVSA) is a clinical-stage biotech developing drugs for the treatment of inflammatory diseases, particularly rare kidney diseases. This chart shows general expectations for the kidney pharmaceutical sector. It reflects experts' confidence in the success of R&D in this complex and risky field.
Analysts' consensus forecast for the overall market share price
ZyVersa Therapeutics (ZVSA) is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, including kidney disease. This is a high-risk research endeavor. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ZyVersa Therapeutics
ZyVersa is a biotech R&D company focused on inflammation. Their R&D pipeline (inhibitors) targets inflammatory pathways (inflammasomes), which they believe are the cause of kidney disease (CKD) and lung disease. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Pharma kidney
ZyVersa (ZVSA) is a kidney and inflammation pharma company. They are developing drugs targeting inflammasomes, key proteins that cause inflammation in kidney diseases. This is niche R&D. This chart compares their composite index to the sector average.
The AKIM Index for the overall market
ZyVersa Therapeutics is a biopharmaceutical company developing drugs for the treatment of kidney (VAR 200) and inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
